BRTX-100 Phase 2 Expanded Data Shows Sustained Pain, Functional Improvements in Lumbar Disc Disease
BRTX sits 20% above its 52-week low of $0.19 on light trading volume (0.1× avg).
Summary
BioRestorative Therapies announced expanded blinded Phase 2 clinical trial data for its BRTX-100 therapy, demonstrating sustained pain and functional improvements in chronic lumbar disc disease. The data, presented at ISCT 2026, included a larger 52-week follow-up cohort of 25 patients, where 52% achieved at least 50% improvement in both VAS pain and ODI function, with no dose-limiting toxicity. This positive update, following the company's prior announcement of an upcoming data presentation, strengthens the clinical narrative for BRTX-100 and supports advancement towards unblinding the full Phase 2 trial and Phase 3 readiness. For a micro-cap biotech with going concern warnings, this clinical progress is a material positive development.
At the time of this announcement, BRTX was trading at $0.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.8M. The 52-week trading range was $0.19 to $2.05. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.